Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07018947 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

Study acronym: ASPIRE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Nov 2030 to Jun 2031
    • Start date changed from estimate of Nov 2025 to Jun 2, 2026
    • Study sites: 13 to 12
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma.
Trial Details
NCT Number NCT07018947
Lead Sponsor Fundacion Clinic per a la Recerca Biomédica
Conditions
(from sponsor)		 Resectable Hepatocellular Carcinoma
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov